Abstract:Objectives Sustained alcohol abuse initiates a progressive disease pathogenesis involving simple steatosis, steatohepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. There is mounting evidence that microbes resident in the human intestine represent a key transmissible factor promoting inflammatory diseases including alcoholic liver disease (ALD). However, mechanisms by which gut microbiota synergize with excessive alcohol intake to promote ALD are poorly understood. We have recently revealed a metaorganismal pathway where nutrients in high fat foods can be metabolized by gut microbes to generate trimethylamine (TMA), which is subsequently metabolized by the host enzyme flavin‐containing monooxygenase 3 (FMO3) to produce the pro‐atherogenic metabolite trimethylamine‐N‐oxide (TMAO). Hepatic FMO3 mRNA levels are suppressed in alcoholics and breath levels of TMA correlate with the severity of alcoholic hepatitis. Thus, this study investigates whether pharmacological inhibition of gut microbe‐derived TMA production can blunt ethanol‐induced liver injury Methods and Results We first determined if ethanol feeding would alter circulating TMA and TMAO levels in mice. Acute (6% vol/vol Lieber DiCarli) and chronic (25 days Lieber DiCarli) isocaloric pair‐ and ethanol‐feeding elicited increases in both TMA and TMAO levels. We then employed a novel approach to block TMA production by using a small molecule inhibitor (CC08) targeting the gut microbial TMA‐producing enzyme CutC/D. CC08 treatment effectively abolished ethanol‐elicited increases in TMA and TMAO. In parallel, CC08 treated mice were completely protected against ethanol‐induced hepatic fat deposition, hepatocellular inflammation, and elevated alanine aminotransferase levels. Collectively, these results suggest inhibiting gut microbial production of TMA can blunt ethanol‐induced liver injury. Conclusions Our results establish the TMA/TMAO pathway as an important regulator of ethanol‐induced liver injury. Inhibition of TMA production by utilizing small molecule inhibitors targeting the TMA lyase, such as CC08, may represent a novel therapeutic approach to combat ethanol‐induced liver injury. Support or Funding Information P50 (AA024333‐01)

Endogenous ethanol production in health and disease

A catalog of ethanol-producing microbes in humans

Ethanol-induced changes to the gut microbiome compromise the intestinal homeostasis: a review

Alcohol or Gut Microbiota: Who Is the Guilty?

From intestinal dysbiosis to alcohol-associated liver disease

Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease

Alcohol, the gut microbiome, and liver disease

Dietary Synbiotic Supplementation Protects Barrier Integrity of Hepatocytes and Liver Sinusoidal Endothelium in a Mouse Model of Chronic-Binge Ethanol Exposure

Alcoholic liver disease and intestinal permeability

Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease

The role of the microbiome in liver disease

Gut microbial metabolites in obesity, NAFLD and T2DM

Gut dysbiosis as a driver in alcohol-induced liver injury

Gut microbiota in alcohol-related liver disease: pathophysiology and gut-brain cross talk

Chronic binge drinking-induced susceptibility to colonic inflammation is microbiome-dependent

Ecophysiological consequences of alcoholism on human gut microbiota: implications for ethanol-related pathogenesis of colon cancer

The gut–liver axis and gut microbiota in health and liver disease

Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota

Drugging the Gut Microbiome for the Treatment of Alcohol‐Induced Liver Injury

Genetic Epidemiology of Ethanol Metabolic Enzymes: A Role for Selection

Gut microbiome in alcohol use disorder: Implications for health outcomes and therapeutic strategies-a literature review